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ABSTRACT
In patients with chronic ischemic myocardial dysfunction, late gadolinium enhancement CMR
(LGE-CMR) accurately depicts the regional extent of fibrosis and predicts functional recovery
after revascularization. We hypothesized that the predictive accuracy of LGE-CMR could be
optimized by not only taking into account the transmural extent of hyperenhancement but also
the amount of residual, non-enhanced viable myocardium, and procedure related necrosis. We
studied 45 patients with chronic ischemic left ventricular dysfunction, who underwent cine
and LGE-CMR 1 month before and 3 months after surgical or percutaneous revascularization.
Segmental and global function, scar, presence of a significant residual viable rim (defined as
≥4.5 mm), and procedure related necrosis were fully quantified using standardized methods and
objective thresholds. Sixty percent of segments without hyperenhancement showed functional
improvement at follow-up. No improvement was observed in segments with >75% segmental
extent of hyperenhancement (SEH), while segments with 1–25%, 26–50%, and 51–75% SEH were
4, 8, and 20 times less likely to improve (multilevel analysis, p < 0.001). Thickness of the viable
rim largely paralleled total wall thickness; therefore, the presence of a significant viable rim did
not provide additional diagnostic value beyond SEH. Procedure related necrosis was found in 12
(27%) patients. The presence of procedure related necrosis was the only (negative) predictor of
changes in left ventricular volumes and ejection fraction. In conclusion, we found that functional
outcome after revascularization was influenced by both transmural extent of hyperenhancement
and procedure related necrosis. However, the presence of a significant residual, viable rim was
of no additional diagnostic value.
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INTRODUCTION
Late gadolinium enhancement CMR (LGE-CMR) allows
the accurate visualization and quantification of both acute and
chronic myocardial necrosis (1). There are several ways in
which LGE-CMR may contribute to the assessment of myocar-
dial viability.
First, by quantifying the transmural extent of hyperenhance-
ment, LGE-CMR can predict the likelihood of functional im-
provement after revascularization of chronically ischemic dys-
functional myocardium. Several studies have shown that the
likelihood of functional improvement after revascularization of
chronically ischemic dysfunctional myocardium is inversely re-
lated to the baseline transmural extent of hyperenhancement
(2–4). Second, by relating the transmural extent of necrosis to
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total wall thickness, LGE-CMR can determine the amount of
residual viable tissue within a predefined myocardial region.
Dysfunctional regions with preserved wall thickness and a sig-
nificant rim of viable myocytes within the myocardial wall have
higher likelihood of functional recovery (5). Finally, serial LGE-
CMR can be used to demonstrate and quantify new regions of
hyperenhancement related to procedural myocardial necrosis,
which has been shown to negatively influence functional out-
come (6, 7).
In this study, our goal was to combine all information from
LGE-CMR to evaluate viability in a group of patients with
chronic ischemic myocardial dysfunction. We hypothesized that
the predictive accuracy of LGE-CMR could be optimized by
not only taking into account the transmural extent of hyperen-
hancement but also the amount of residual, non-enhanced viable
myocardium, and the extent of procedure related necrosis. Most
CMR viability studies have used visual assessment of segmental
wall thickening and extent of delayed hyperenhancement. In this
study, all data were analyzed quantitatively, using standardized
methods and objective thresholds.
METHODS
Patients
All patients with known coronary artery disease and regional
wall motion abnormalities on echocardiography or left ventric-
ular angiography, without CMR contraindications, who were
scheduled to undergo surgical or percutaneous revascularization,
were study candidates. The Committee on Research Involving
Human Subjects of the VU University Medical Center, Ams-
terdam, approved the study protocol. All patients gave written
informed consent.
CMR
Imaging was scheduled on a 1.5T scanner (Sonata, Siemens,
Erlangen, Germany) 1 month before and 3 months after revas-
cularization. Segmented steady-state free precession (TE/TR
1.2/3.2 ms; typical voxel size 1.3 × 1.8 × 5 mm) cine im-
ages were acquired at 8 to 10 short-axis views obtained ev-
ery 10 mm, starting at the mitral valve insertion and covering
the entire left ventricle. Ten to 15 minutes after injection of
a gadolinium-based contrast agent (Magnevist, Schering AG,
Berlin, Germany; 0.2 mmol/kg), contrast-enhanced images were
acquired in the same orientation as the cine images using a
2D segmented inversion recovery gradient-echo pulse sequence
(typical voxel size 1.6 × 1.3 × 5.0 mm).
Definition of segments
Images were evaluated using a 16-segment model (8), divid-
ing the left ventricle into 6 basal, 6 midventricular, and 4 distal
segments. By convention, the most basal short-axis slice used
for analysis was located just below and exclusive of the left ven-
tricular outflow tract. The 2 most apical slices were excluded
because short-axis images at this level preclude a reliable seg-
mental evaluation due to small diameter. To compose the basal,
midventricular, and distal segments, data of a maximum of 3
short-axis slices were averaged.
Complete revascularization was defined as revascularization
of all vessels with >50% diameter stenosis. For patients in whom
revascularization was incomplete, only segments in revascular-
ized coronary artery territories were considered (8).
Functional analysis
All data were analyzed on a separate workstation (Sun
Microsystems, Inc., Santa Clara, California, USA) using
a dedicated software package (Mass, Medis, Leiden, The
Netherlands). Segmental wall thickness was measured at end-
systole and end-diastole by the modified center line method (9)
after manual tracing of endocardial and epicardial borders in
stop-frame images, excluding trabeculae and papillary muscles.
Segmental wall thickening (SWT) in millimeters was calculated
as: end systolic wall thickness–end diastolic wall thickness. The
normal range of SWT was defined in a group of 10 healthy vol-
unteers (age 50–75 years): 4.4 ± 0.7 mm. Segments with SWT
<3 mm (mean–2SD) were considered dysfunctional. Regis-
tration of follow-up cine images was achieved using standard
imaging procedure and various anatomical landmarks, such as
right ventricle septal insertion sites, papillary muscle location,
and trabecularization patterns in the right and left ventricles.
Functional improvement was defined as increase in SWT of
≥1.5 mm, based on the in-plane spatial resolution of the cine
sequence. Inter- and intraobserver variabilities of SWT analysis
(defined in 10 randomly chosen patients) were 0.1 ± 0.7 mm
and 0.0 ± 0.4 mm, respectively (mean difference ± SD).
Left ventricular volumes were normalized to body surface
area (m2). Both intra- and interobserver variability of left ven-
tricular volume measurements were 1 ± 3%. A change of >7%
(=intraobserver variability + 2 SD) in left ventricular volumes
at follow-up was considered significant.
Hyperenhancement analysis
Areas of hyperenhancement were quantified by computer-
assisted planimetry on each of the short axis images, and seg-
mental extent of hyperenhancement (SEH, expressed as percent-
age of segmental area) was calculated. Hyperenhancement was
defined as signal intensity ≥5 SD above the signal intensity of
remote myocardium in the same slice (10). Segments were as-
signed to one of the following SEH groups: 1–0%, 2–1 to 25%,
3–26 to 50%, 4–51 to 75%, and 5–76 to 100% hyperenhance-
ment. Using an assumed density of 1.05 g/mL (11), total my-
ocardial scar in grams per patient was calculated by summation
of hyperenhanced regions in all slices. Inter- and intraobserver
variability of total myocardial scar calculation were 1.2 ± 4.1 g
and 0.8 ± 1.6 g, respectively,(mean difference ± SD). A sig-
nificant increase in total myocardial scar was defined as ≥4 g
(intraobserver variability + 2 SD). Mean segmental thickness of
the non-enhanced, viable rim was calculated as: total segmen-
tal wall thickness*(100%–SEH). A viable rim of ≥4.5 mm was
considered thick (5).
To assess the relation between changes in global function and
viability, we defined a viability index for each patient as: (the
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number of dysfunctional segments with SEH ≤ 25% divided by
the total number of dysfunctional segments) * 100%.
Statistical analysis
All values are expressed as mean ± SD. The paired sam-
ple t test and the independent samples t test were used to
compare means within the study group or between subgroups.
We used multilevel logistic regression to adjust for the non-
independence of the data (MlwiN, version 1.02.0007, Centre
for Multilevel Modelling, London, United Kingdom) (12, 13)
to evaluate the relations between hyperenhancement and wall
thickening. Results are given as odds ratios, relating the func-
tional outcome of segments with hyperenhancement to that of
segments without hyperenhancement. Correlation between to-
tal segmental wall thickness and viable rim thickness and SEH
and viable rim thickness was assessed using regression analy-
sis for mixed models (SPSS, version 12.0, Chicago, IL). Uni-
variable and multivariable logistic regression analysis was per-
formed to find predictors of global functional improvement,
using categorical variables (gender, history of previous my-
ocardial infarction, cardiac risk factors [diabetes, hyperten-
sion, hypercholesterolemia, smoking], medical therapy [ACE
inhibitors, β-blockers], mode and completeness of revascular-
ization, occurrence of post-procedural new hyperenhancement,
and biochemical evidence of peri-operative myocardial infarc-
tion [CK-MB >3 × upper limit of normal], and continuous vari-
ables [age, baseline LV volumes, ejection fraction, and viability
index]). p < 0.05 was considered statistically significant.
RESULTS
Fifty patients were initially included in the study protocol.
Four patients declined to return for follow-up, and 1 patient was
excluded because coronary artery bypass surgery was accompa-
nied by left ventricular aneurysmectomy. Coronary artery bypass
surgery was performed in 32 patients, and percutaneous trans-
luminal coronary angioplasty in 13. CMR was performed 4 ± 2
weeks before and 14 ± 2 weeks after revascularization. There
were no ischemic events in the period between the CMR exami-
nations and revascularization. Baseline characteristics of the pa-
tient population are listed in Table 1. Complete revascularization
was achieved in 27 of the 32 surgically treated patients. Eight
of the 9 patients with multivessel disease in the PTCA group
revascularization was ischemia-driven and, therefore, limited to
the most significant lesion.
Regional ventricular function
Of 720 available segments, 644 (89%) were successfully
revascularized. Of 356 dysfunctional segments at baseline (mean
SWT 1.3 ± 1.1 mm), 322 (90%) were revascularized. Three
months after revascularization, 85 (26%) showed functional im-
provement: 43 of 72 (60%) segments without hyperenhance-
ment; 21 of 76 (28%) segments with 1–25% SEH; 15 of 76
(20%) segments with 26–50% SEH; 6 of 74 (8%) segments
with 51-75% SEH; and in none of 24 segments with 76–100%
SEH. The likelihood of functional improvement at follow-up de-
Table 1. Patients characteristics
Males/females, n 38/7
Age (yrs) 62 ± 9
Risk factors, n (%)
Systemic hypertension 10 (22)
Diabetes mellitus 11 (24)
Hypercholesterolaemia 33 (74)
Smoking 14 (30)
Positive family history 7 (15)
Coronary angiography, n (%)
Single-vessel disease 4 (9)
Two-vessel disease 13 (28)
Three-vessel disease 28 (63)
History of myocardial infarction, n (%) 28 (63)
Previous revascularization, n (%)
CABG 2 (4)
PTCA 6 (13)
Ejection fraction at baseline (%) 39 ± 11
Months between infarction and baseline CMR (range) 53 (2–177)
Cardiac medication, n (%)
B-blockers 33 (74)
ACE inhibitors 20 (44)
Aldosterone antagonists 6 (13)
Diuretics 22 (48)
Nitrates 4 (9)
Ca-channel blockers 6 (13)
Aspirin 28 (63)
Acenocoumarol 22 (48)
Antilipid agents 33 (74)
CABG = coronary artery bypass grafting, PTCA = percutaneous
transluminal coronary angioplasty.
creased with increasing SEH: segments with 1–25%, 26–50%,
and 51–75% SEH were 4, 8, and 20 times less likely to have
functional improvement than segments without hyperenhance-
ment (multilevel analysis, p < 0.001).
Viable rim
Of the 322 preoperative dysfunctional segments, 209 (65%)
had a viable rim of ≥4.5 mm. In our study group, total segmen-
tal wall thickness and thickness of the viable rim were strongly
correlated (regression analysis for mixed models, p < 0.001).
Consequently, viable rim thickness was inversely related to the
transmural extent of hyperenhancement (Fig. 1) and had no di-
agnostic value beyond SEH alone. Almost all (147 of 148, 99%)
segments with ≤25% SEH had a thick viable rim, whereas the
large majority of segments with >50% SEH (92 of 98, 94%) only
had a thin rim of non-enhanced, viable myocardium (Fig. 2). Of
76 segments with 26-50% SEH, 54 (71%) had a preserved viable
rim. Functional improvement after revascularization was seen in
20% of these segments versus 18% for segments without a thick
viable rim (p = NS).
Periprocedural hyperenhancement
LGE-CMR demonstrated hyperenhancement in 41 of the
45 patients at baseline (mean total myocardial scar 21 ± 16,
range 3–80 g). After revascularization, scar mass increased in
11 patients (9/2 coronary artery bypass surgery/percutaneous
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Figure 1. Relation between Viable rim thickness, Segmental Ex-
tent of Hyperenhancement and Segmental wall thickness. Thresh-
old value of 4.5 mm to differentiate between thin and thick viable
rim is indicated by the dashed lines.
transluminal coronary angioplasty) and 1 surgically treated pa-
tient without myocardial scar at baseline developed new hyper-
enhancement. Mean total increase in total myocardial scar was
quantified at 9.8 ± 5.4 g (range 4.0–19.7 g). Fig. 3 shows an
example of new hyperenhancement in a patient after surgical
revascularization in a region not related to baseline scar. The
majority of the patients with periprocedural enhancement had
extensive coronary artery disease: there were 1, 2, and 8 patients
with single, two-, and three-vessel disease, respectively. Crea-
Figure 2. Viable rim thickness according to Segmental Extent of
Hyperenhancement (SEH).
tine kinase-MB isoenzyme measurements were obtained in all
32 surgical patients at 6, 12, 24 and 48 hours after the procedure.
Only 4 patients with increased total myocardial scar had elec-
trocardiographic (new Q waves) and/or biochemical evidence
(creatine kinase-MB isoenzyme elevation >3 times the upper
normal limit) (14) of perioperative myocardial infarction. Thir-
teen patients had smaller degrees of scar expansion, less than
our predefined cutoff value of 4 g (see Methods), with mass
range of 1.4–3.6 g. None of these patients had elevated cardiac
enzymes or new Q waves.
After revascularization, SEH score increased in 60 segments
(mean number of segments per patient 5 ± 2, range 2–9 seg-
ments). Among those there were 26 pre-operative normal seg-
ments, 5 of which became dysfunctional at follow-up. Another
34 segments were already dysfunctional at baseline. Postopera-
tive new enhancement was seen in 16% of segments that failed
to improve: 6 of 29 (21%) segments with 0% SEH; 8 of 55 (15%)
segments with 1–25% SEH; 9 of 61 (15%) segments with 26–
50% SEH; and 11 of 68 (16%) segments with 51–75% SEH
at baseline. There was no significant relation between the pres-
ence of myocardial scar at baseline and occurrence of postop-
erative new hyperenhancement (multilevel regression analysis,
p = NS).
Global ventricular function
After revascularization, ejection fraction improved in 20 pa-
tients (mean change 4 ± 3%), while it remained unchanged or
worsened in 25 patients (mean change −4 ± 4%). Univariable
predictors of changes in ejection fraction and left ventricular
volumes are shown in Table 2. The occurrence of new hyperen-
hancement after revascularization was the only (negative) multi-
variable predictor of change in ejection fraction (odds ratio 0.13,
95% confidence interval 0.02 to 0.74, p = 0.02) and end-systolic
and end-diastolic volumes (odds ratio 0.01, 95% confidence in-
terval 0 to 0.24, p = 0.01 and odds ratio 0.07, 95% confidence
interval 0.01 to 0.54, p = 0.01, respectively).
DISCUSSION
The major findings of our study are as follows. First, we found
that the likelihood of segmental functional improvement after
revascularization was inversely related to the segmental extent
of hyperenhancement on LGE-CMR in patients with chronic
ischemic left ventricular dysfunction. Second, thickness of the
viable rim largely paralleled total segmental wall thickness and,
therefore, did not add to the predictive power of the segmental
extent of hyperenhancement alone. Third, periprocedural necro-
sis was found in a significant part of our study population (27%)
and was the only (negative) predictor of changes in global left
ventricular function and volumes.
Prediction of functional improvement:
a quantitative approach
We specifically chose to use quantitative analysis for this
study. Although valid for most clinical purposes, qualitative as-
sessment of wall motion and extent of hyperenhancement may
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Figure 3. Midventricular short axis LGE-CMR image demonstrating hyperenhancement before surgery (A, white arrow) and new hyperenhance-
ment after surgery (B, dotted arrow) in a patient without enzymatic or electrocardiographic perioperative infarction.
lead to inaccuracy related to intra- and interobserver variabil-
ity. All methods were standardized (ie, data acquisition, con-
tour delineation, DE-image window settings, etc.), and objec-
tive thresholds derived from reproducibility studies were used
to calculate segmental and global function and scar extent. In
addition, we used multilevel logistic regression for the evalu-
ation of the segmental changes, which takes into account the
nonindependence of segmental data. Our results clearly demon-
strate the inverse relation between extent of hyperenhancement
and functional outcome: segments with 1–25%, 26–50%, and
51–75% SEH were 4, 8, and 20 times less likely to have func-
tional improvement than segments without hyperenhancement.
The negative predictive value was high: no segments with >75%
SEH and only 5% with >50% SEH improved.
The overall rate of improvement (26%; 85 of 322 segments)
and the positive predictive value (60% of segments without hy-
Table 2. Predictors of global functional improvement: univariable analysis
EF ↑ EF ↓ or = LVEDVI ↓ LV EDVI ↑ or = LVESVI ↓ LVESVI ↑ or =
(n = 20) (n = 25) p (n = 20) (n = 25) p (n = 18) (n = 27) p
Age, y 62 ± 12 61 ± 8 0.74 58 ± 11 65 ± 7 0.02 60 ± 11 63 ± 8 0.25
Men, n 15 23 0.14 17 21 0.93 14 24 0.32
LV EDVI, mL/m2 117 ± 31 120 ± 32 0.69 125 ± 24 113 ± 35 0.18 128 ± 21 112 ± 35 0.09
LV ESVI, mL/m2 75 ± 29 72 ± 29 0.76 78 ± 23 70 ± 32 0.34 80 ± 23 69 ± 31 0.24
LV EF, % 37 ± 11 41 ± 9 0.19 39 ± 10 40 ± 11 0.59 39 ± 11 40 ± 10 0.64
Viability index 22 ± 14 20 ± 11 0.49 22 ± 14 20 ± 12 0.72 23 ± 14 20 ± 12 0.44
Previous infarction, n 14 15 0.49 15 14 0.19 13 16 0.37
Periprocedural hyperenhancement, n 2 10 0.04 2 10 0.04 1 11 0.03
CABG, n 14 18 0.88 15 17 0.61 14 18 0.42
Complete revascularization, n 15 16 0.43 15 16 0.43 15 16 0.10
Diabetes, n 5 6 0.94 6 5 0.44 4 7 0.78
Hypertension, n 2 7 0.15 4 5 1.00 3 6 0.65
Smoking, n 6 8 0.89 5 9 0.43 3 11 0.10
Hypercholesterolemia 2 6 0.24 2 6 0.24 2 6 0.35
ACE inhibitors 13 12 0.26 14 11 0.09 14 11 0.02
β-blockers 17 16 0.12 15 18 0.82 13 20 0.89
CABG = coronary artery bypass grafting, CK-MB = creatine kinase – MB isoenzyme, LV EDVI = Left Ventricular End-Diastolic Volume Indexed,
LV EF = Left Ventricular Ejection Fraction, LV ESVI = Left Ventricular End-Systolic Volume Indexed, ULN = Upper Limit of Normal.
perenhancement and 43% with ≤25% SEH) were lower than
in recent studies using LGE-CMR (2–4, 6). Schinkel et al re-
cently studied 258 patients with ischemic cardiomyopathy using
echocardiography and found an almost identical improvement
rate of 27% 3–6 months after coronary artery bypass surgery
(15). The higher improvement rates from other LGE-CMR stud-
ies may be partly explained by the variable time course of im-
provement of viable myocardium. This may be considerably
prolonged, and a longer follow-up time interval may be required
to view the full extent of improvement (16, 17).
Viable rim
Baer et al (18) showed that preserved end-diastolic wall thick-
ness >5.5 mm (defined with cine CMR) has high sensitivity
for the prediction of functional recovery after revascularization.
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Specificity, however, is low, which may be explained by the fact
that segments with preserved wall thickness may consist of var-
ious degrees of myocardial scar. Theoretically, segments with
intermediate ranges of scar extent (25–75%) could still show
functional improvement if wall thickness and the residual vi-
able rim were preserved. Knuesel et al (5) recently compared
LGE-CMR and 18F-Fluorodeoxyglucose positron emission to-
mography (FDG-PET) and found that a residual non-enhancing
(thus viable) rim of 4.5 mm corresponded to a 50% FDG-uptake.
In their study, metabolically active segments with a preserved
viable rim had a high improvement rate (85%). Thin, metaboli-
cally inactive segments and segments with either reduced FDG-
uptake or a thin viable rim all had a low likelihood of improve-
ment (13%, 23%, 36%, respectively). We sought to improve the
diagnostic accuracy of LGE-CMR by also taking into account
the presence of a significant residual viable rim, which can eas-
ily be determined on the contrast images. However, in our study,
98% of the segments with 0–25% SEH had a viable rim of at
least 4.5 mm, while 94% segments with 50–100% SEH had a
viable rim of <4.5 mm. Therefore, the presence or absence of
viable rim had no diagnostic importance in these categories. In
segments with 25–50% SEH, the presence of a viable rim re-
sulted in a non-significant, slightly better functional outcome:
20% improvement vs. 18%. However, the number of segments
with intermediate hyperenhancement was limited, and further
study is required to establish the added value of preserved wall
thickness and a significant residual, non-enhancing viable rim.
Procedural myocardial necrosis
Selvanayagam et al recently reported on the incidence and
extent of revascularization related myocardial injury (6, 7, 19).
Using LGE-CMR, these authors found new regions of hyper-
enhancement in 38% and 28% of patients after coronary artery
bypass grafting and percutaneous coronary intervention, respec-
tively. Using a 56 segment left ventricular model, they observed
that, after surgery, 36% of segments with ≤25% SEH that did not
improve had evidence of surgery related necrosis. In our mixed
coronary artery bypass grafting and percutaneous coronary in-
tervention population, we had comparable results: 12 of 45 pa-
tients (27%) demonstrated new regions of hyperenhancement at
follow-up, and likely contributed to the non-recovery of 17%
of 84 segments with no or minimal hyperenhancement (≤25%
SEH). In addition, we found that procedure related necrosis
was the only (negative) multivariable predictor of changes in
global left ventricular volumes and function. These data con-
firm the prognostic relevance of myocardial necrosis sustained
during revascularization and imply that considerable gain may
be achieved by optimizing periprocedural myocardial protection
and aggressive medical treatment to prevent early graft failure.
Limitations
Data of several short axis slices were averaged for the 16
segment left ventricular model that we used because this is com-
monly used in daily practice. Although averaging of information
obligatory causes some loss in detail, it may be less sensitive
to misregistration that is always a potential source of error in
follow-up studies. In our hospital, creatine kinase-MB isoen-
zyme is routinely used to identify revascularization procedure
related myocardial necrosis. The use of troponins might have
increased the enzymatic detection of periprocedural myocardial
damage (20).
CONCLUSIONS
We performed a quantitative evaluation of LGE-CMR-
derived parameters of myocardial viability in patients with
chronic ischemic left ventricular dysfunction before and after
revascularization. In line with previous studies, the transmural
extent of hyperenhancement was inversely related to the likeli-
hood of functional improvement. In our study, the presence of
a significant viable rim was of no additional diagnostic value.
Procedure related myocardial necrosis was a frequent finding
and was the only multivariable predictor of changes in global
function and volumes.
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